CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 327 enrolled
Drug / intervention
ciclesonide +1 moredrug
Likely dose
ciclesonide 74 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01401465
NCT01401465Phase 3Completed
CompareCT.gov

A Randomized Two Period Two-Way Crossover Study To Evaluate Patient Preference, Satisfaction And Efficacy Of A Nasal Aerosol Versus An Aqueous Nasal Spray Used For The Treatment Of Allergic Rhinitis

Sumitomo Pharma America, Inc.·interventional·Posted Jul 25, 2011·Updated Apr 30, 2013

In Brief

A Phase 3 clinical trial evaluating ciclesonide and mometasone for Perennial Allergic Rhinitis. Completed, enrolled 327 participants across 15 sites.

Detailed Summary

This is a randomized, multicenter, 2-way crossover study in subjects 12 years or older with perennial allergic rhinitis (PAR) to evaluate patient preference, satisfaction and efficacy of ciclesonide nasal aerosol versus mometasone aqueous nasal spray. A novel patient-administered assessment, developed and validated to measure patient satisfaction with and preference of intranasal corticosteroids (INCS) for the treatment of allergic rhinitis (AR), is utilized in this study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPerennial Allergic Rhinitis
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 25, 2011
Enrollment StartJul 1, 2011
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 14.9 years ago

Interventions

ciclesonidedrug

74 mcg ciclesonide nasal aerosol once daily

mometasonedrug

200 mcg mometasone aqueous nasal spray once daily